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Abstract
Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation pro-
cess. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Yet, allosteric inhibition of FXIIIa is a paradigm that may offer a key advantage of controlled
inhibition over orthosteric inhibition. Such an approach is likely to lead to novel FXIIIa inhibi-
tors that do not carry bleeding risks. We reasoned that targeting a collection of basic amino
acid residues distant from FXIIIa’s active site by using sulfated glycosaminoglycans (GAGs)
or non-saccharide GAGmimetics (NSGMs) would lead to the discovery of the first allosteric
FXIIIa inhibitors. We tested a library of 22 variably sulfated GAGs and NSGMs against
human FXIIIa to discover promising hits. Interestingly, although some GAGs bound to
FXIIIa better than NSGMs, no GAG displayed any inhibition. An undecasulfated quercetin
analog was found to inhibit FXIIIa with reasonable potency (efficacy of 98%). Michaelis-
Menten kinetic studies revealed an allosteric mechanism of inhibition. Fluorescence studies
confirmed close correspondence between binding affinity and inhibition potency, as
expected for an allosteric process. The inhibitor was reversible and at least 9-fold- and 26-
fold selective over two GAG-binding proteins factor Xa (efficacy of 71%) and thrombin,
respectively, and at least 27-fold selective over a cysteine protease papain. The inhibitor
also inhibited the FXIIIa-mediated polymerization of fibrin in vitro. Overall, our work presents
the proof-of-principle that FXIIIa can be allosterically modulated by sulfated non-saccharide
agents much smaller than GAGs, which should enable the design of selective and safe
anticoagulants.
Introduction
Thrombotic disorders, such as venous thromboembolism (VTE), stroke, myocardial infraction
and other indications, constitute a major health burden for most countries. Even with the
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current repertoire of antithrombotics used in the clinic, a large number of patients develop
recurrent VTE and/or suffer from major long-term complications [1–3]. A growing body of lit-
erature suggests that VTE and cancer are strongly linked. Patients with cancer have at least
4-fold increased risk for VTE and patients with VTE are at higher risk for developing cancer
[4]. A range of anticoagulants is used in the clinic today to treat and prevent episodes of throm-
bosis including the antithrombin-based agents (heparins), vitamin K-based agents (couma-
rins), and the newer direct thrombin or factor Xa inhibitors [5]. Despite their success, each
agent carries a number of drawbacks, of which a common risk is internal bleeding, which can
be life-threatening [6]. Thus, approaches that seek completely different routes of engineering
anticoagulant activity, with a promise of reducing bleeding complications, are important to
develop.
Among these newer approaches is the concept of targeting factor XIIIa (FXIIIa), which cata-
lyzes the final step in the coagulation process by cross-linking the α- and γ-chains of fibrin.
FXIIIa is the only enzyme of the coagulation system that is not a serine protease. It is a thiol-
based transglutaminase that conjugates two substrates in a process that involves formation of a
thio-ester-based acyl enzyme intermediate [7,8]. This intermediate, instead of being acted
upon by a molecule of water to afford a cleaved product as for serine proteases, is acted upon
by a nearby amine (Lys residue) of the second substrate to give the coupled product. Absence
of this lysine can induce hydrolysis of the thio-ester intermediate resulting in an incomplete
conjugation step [7,8].
FXIIIa can also cross-link α2-plasmin inhibitor to fibrin, which helps protect the newly
formed clot from plasmin-mediated fibrinolysis [9]. This contributes to the clot’s higher bio-
chemical and biophysical stability. In addition, the size of thrombus is also dependent on
FXIIIa action [10, 11]. In fact, a model of ligation-mediated thrombosis of the mouse inferior
vena cava showed that FXIII-deficiency resulted in a significant reduction (~50%) in thrombus
weight arising from a reduced RBC content [10, 11]. This implies that chemical inhibition of
FXIIIa may lead to weaker and smaller thrombus formation, which may be more susceptible to
fibrinolysis. In fact, tridegin, a peptide from leech Haementeria ghilianii that inhibits FXIIIa,
does reduce clot strength and stability [12–16]. This, when coupled with the observation that
heterologous FXIII gene knockout in the mouse is not associated with signs of excessive bleed-
ing [10,17,18], suggests that the transglutaminase FXIIIa may serve as a promising therapeutic
target to prevent and/or treat VTE and other thrombotic disorders.
Despite the apparent advantages, very few FXIIIa inhibitors have been reported in literature.
Tridegin is the most studied inhibitor [12–16]. It is a 66-mer polypeptide that will be challeng-
ing to transform into a small molecule scaffold. Small molecule inhibitors of FXIIIa reported to
date include active site-directed irreversible agents [19], imidazolium salts, [20] thiadiazoles
[21] and cyclopropenoids [22]. These, and other miscellaneous agents [19], were developed as
early leads and/or probes of FXIIIa mechanism, and appear to have not been followed up with
advanced studies.
A priori, the double-displacement mechanism offers more opportunities of interfering with
the catalytic cycle because two substrates have to be engaged in succession [23]. Such fine regu-
lation is likely to be highly susceptible to minor changes in conformation of the active site. We
thus hypothesized that allosteric modulation of FXIIIa’s active site should be achievable. In
principle, allosteric inhibition can offer two major advantages including 1) higher target speci-
ficity and 2) better regulation of activity in comparison to orthosteric inhibitors [24–30]. Of
these, the latter point is especially important for FXIIIa because complete elimination of this
enzyme has been known to result in bleeding diathesis [31–33], whereas partial reduction in its
activity results in only minor adverse effects [10, 17, 18]. As demonstrated for thrombin earlier
[34–38], allostery is the only process for engineering partial inhibition. Therefore, discovering
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allosteric inhibitors of FXIIIa is likely to open up a major route to novel molecules that could
eventually afford safer anticoagulants.
With this objective, we tested a library of 22 variably sulfated glycosaminoglycans (GAGs)
and their nonsaccharide mimetics against human FXIIIa (Fig 1). An undecasulfated quercetin
trimer 13 was identified as a promising inhibitor that displays allosteric inhibition mechanism.
The agent inhibited the FXIIIa-mediated crosslinking of fibrin suggesting its potential as a
promising lead. Overall, this work presents the first mechanistic evidence that FXIIIa can be
allosterically modulated by appropriate small molecules that may display effective and safe
anticoagulation properties.
Results and Discussion
Rationale for Screening Sulfated Molecules against Human FXIIIa
Plasma FXIII is a heterotetramer of two A and two B subunits (FXIIIA2B2). The A subunit
(FXIII-A) contains the catalytic domain and the B subunit (FXIII-B) serves as a carrier and reg-
ulatory protein. FXIIIA2B2 is activated by thrombin through cleavage of Arg37–Gly38 bond of
A subunits, which is followed by dissociation of the B subunits in the presence of Ca2+. The
resulting FXIIIa has a reactive Cys314 residue in the active site, which cross-links Lys and Gln
residues of fibrin α- and γ- chains leading to a three-dimensional, insoluble fibrin network [9,
39]. The A subunit of FXIIIa has a relatively high number of Lys and Arg residues that are clus-
tered together on the surface potentially forming an anion-binding exosite (Fig 2A and 2B),
Fig 1. The library of sulfated GAGs and NSGMs.Molecules in this library possessed structural diversity at multiple levels, e.g., different core
scaffolds, number of sulfate groups, and position of sulfate groups. NSGMs included five distinct chemical classes of pentasulfated monomeric
flavonoid scaffolds (1–2), hexa- and octa- sulfated dimeric flavones (3–9), pentasulfated dimeric flavone-quinazolinones (10–12), undecasulfated
trimeric flavones (13 and 14), and dodecasulfated hexabenzoyl inositol derivative (15). GAGs comprised of unfractionated heparin (UFH, 16),
enoxaparin (17), and chondroitin sulfate A-C (19–21) in addition to the octasulfated pentasaccharide fondaparinux (18) and the octasulfated
disaccharide sucrose octasulfate (22).
doi:10.1371/journal.pone.0160189.g001
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which is located ~16–24 Å from the enzyme active site. Although this exosite bears no homol-
ogy with thrombin’s exosite 2, which interacts with heparin (Fig 2C and 2D) [40], it may
potentially serve as an allosteric site to which the sulfated GAGs and/or non-saccharide
mimetics of GAGs may bind and inhibit FXIIIa. Interestingly, a site on a homologous enzyme,
transglutaminase 2, was recently identified as the heparin binding site and this site appears to
be important for enzyme function [41,42]. A characteristic feature of these sites is that they
contain multiple Arg/Lys residues, which most probably interact with multiple sulfate groups
on heparin and related GAGs. Yet, these Arg/Lys residues are distinct in terms of the location
and orientation. Further, these sites differ in terms of their hydrophobic sub-sites [41–43],
which may serve as recognition elements for sulfated nonsaccharide GAG mimetics (NSGMs),
as demonstrated earlier [37, 38, 44–46]. This led to our hypothesis that one of the GAGs and/
or NSGMs, which electrostatically and/or hydrophobically complements the anion-binding
site, may transmit binding energy to the active site and function as selective allosteric inhibitor
(s) of FXIIIa.
To test this hypothesis, we studied a focused library of 22 variably sulfated GAGs and sul-
fated NSGMs (Fig 1). NSGMs included five distinct chemical classes of pentasulfated mono-
meric flavonoids (1 and 2), hexa- and octa-sulfated dimeric flavones (3–9), pentasulfated
dimeric flavone-quinazolinones (10–12), undecasulfated trimeric flavones (13 and 14), and
dodecasulfated hexabenzoyl inositol derivative (15). The group of GAGs included natural
sequences of unfractionated heparin (UFH, 16), enoxaparin (17), and chondroitin sulfate A-C
(19 and 21), as well as synthetic molecules such as the octasulfated pentasaccharide fondapari-
nux (18) and the disaccharide sucrose octasulfate (22). Thus, the focused library afforded
Fig 2. The putative anion-binding allosteric site of human FXIIIa. (A) The electrostatic potential of the surface exposed anion-binding site of
FXIII (PDB ID: 1GGU). (B) The basic residues in the site are shown as spheres. The residues matching the heparin-binding site of
transglutaminase are K61, K73, R303, and K678. (C) The electrostatic potential of human thrombin is shown (PDB ID: 1XMN). (D) The basic
residues of thrombin’s exosite 2 are shown in spheres. Positive and negative potentials are colored in blue and red, respectively.
doi:10.1371/journal.pone.0160189.g002
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excellent diversity of core scaffolds, orientation of sulfate groups and sulfation level so as to
ensure higher probability of discovering allosteric inhibitors.
Inhibition of Human FXIIIa by the Library of Sulfated Molecules
The library of sulfated molecules was screened for inhibition of human FXIIIa using a modified
bisubstrate, fluorescence-based transglutamination assay, as described earlier [47]. Dansylcada-
verine and N,N-dimethyl-casein were used as two substrates, which upon FXIIIa-dependence
conjugation show a marked increase in fluorescence at 550 nm (λEX = 360 nm). Initial screen-
ing was performed at 200 μMNSGM concentration (1–15) or 50–1110 μMGAG concentra-
tion (16–22) (Table 1). At these levels, none of GAGs inhibited FXIIIa by more than 5%.
Sucrose octasulfate (22) inhibited FXIIIa by about 17 ± 2%. Interestingly, NSGMs displayed
varying inhibition potential. Pentasulfated 1 and 2, a flavone and flavanol monomers, respec-
tively, inhibited FXIIIa by ~30%, whereas polysulfated, homo or heterodimeric flavonoids 3–
12 exhibited inhibition levels of 53 to 89%. Of these, the octasulfated homodimeric flavone 6
was the most efficacious (89% inhibition). Trimeric scaffolds 13 and 14 inhibited FXIIIa by
94% and 29%, respectively. Interestingly, the dodecasulfated hexabenzoyl inositol derivative 15
inhibited FXIIIa only 55% at 200 μM concentration. To identify promising NSGMs from these,
screening was performed at a lower concentration (20 μM). The results showed 3, 6, 7 and 10
Table 1. Inhibition Percent of Human FXIIIa by Sulfated Small Molecules.a
Molecule No. of sulfates FXIIIa inhibition at 200 μM (%) FXIIIa inhibition at 20 μM (%)
1 5 31 ± 4b NDc
2 5 32 ± 6 ND
3 8 65 ± 3 26 ± 2
4 8 67 ± 5 ND
5 8 76 ± 4 ND
6 8 89 ± 5 40 ± 3
7 8 58 ± 4 31 ± 3
8 6 84 ± 5 ND
9 8 53 ± 5 ND
10 5 88 ± 7 27 ± 1
11 5 81 ± 7 ND
12 5 80 ± 6 ND
13 11 94 ± 4 55 ± 2
14 11 29 ± 6 ND
15 12 55 ± 7 ND
16 Variable ~2 (at 250 μM) ND
17 Variable ~3 (at 1110 μM) ND
18 8 ~0 (at 360 μM) ND
19 Variable ~1 (at 50 μM) ND
20 Variable ~0 (at 50 μM) ND
21 Variable ~0 (at 50 μM) ND
22 8 17 ± 2 ND
a The percentages of inhibition of human FXIIIa by different sulfated molecules were monitored by a transglutamination assay using a bisubstrate-based
ﬂuorescence spectroscopy (λEx = 360 nm and λEm = 550 nm) in 50 mM TrisHCl (pH 8.0) containing 10 mM CaCl2 and 100 mM NaCl at 37°C. See Materials
and Methods for details.
b Errors represent ± 1 S.E.
c Not determined.
doi:10.1371/journal.pone.0160189.t001
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induced 27 to 40% inhibition, whereas 13 inhibited FXIIIa by 55% (Table 1). Thus, the mole-
cule that exhibited the most potent inhibition at 20 μMwas the flavone trimer 13.
To measure the potency and efficacy of inhibitor 13, the dose-dependence of FXIIIa inhibi-
tion was evaluated using the logistic Eq 1 (see Table 2). The potency of inhibition refers to the
IC50 (x-axis), whereas the efficacy refers to the net change in residual FXIIIa activity (ΔY) (y-
axis). Representative inhibition profiles are shown in Fig 3A. Molecule 13 inhibited FXIIIa
with an IC50 of 36.2 μM and efficacy of 98%. These inhibition parameters were independent of
enzyme concentration (see S1 Table). The structurally related trimer 14 inhibited FXIIIa with a
much weaker potency (118.0 μM) and an almost equivalent efficacy (93%). Iodoacetamide, a
nonselective inhibitor of thiol-containing enzymes, was used as a positive control. It inhibited
human FXIIIa with an IC50 of 2.9 μM (efficacy = ~100%, Table 2).
We also evaluated NSGM 13 against guinea pig transglutaminase (gTG), a very closely
related enzyme. NSGM 13 inhibited gTG in a comparable manner with an IC50 of 23.5 μM and
an efficacy of 87% (Table 2). Although gTG is not relevant for application with regard to
humans, it would be important to engineer an analog of 13 that displays higher selectivity
against human transglutaminases.
Structure-Activity Relationship of Human FXIIIa Inhibition
To develop a better understanding for structural elements required for FXIIIa inhibition by these
inhibitors, we closely re-examined their structures and their corresponding inhibition profiles.
The monomeric flavonoids were the weakest inhibitors among all NSGMs irrespective of the cen-
tral moiety being either unsaturated (1) or saturated (2). Coupling of two flavone moieties using
alkylene linkers to form dimeric scaffolds generally improved the inhibition potential by at least
2-fold. Within this category, increasing the linker length from 2-atom (3) to 4-atom (6) enhanced
the inhibition efficacy from 65% to 89% (at 200 μM) and from 26% to 40% (at 20 μM). Yet, a
trans double bond (7) or a longer linker (5-atom, 9) was detrimental. This suggests that the
4-atom linker appears to be an optimal length for the 5–5-linked dimeric NSGMs. Interestingly,
shifting the sulfate group from position-3ˋ (dimer 7) to position-2ˋ (dimer 5) increased the inhi-
bition efficacy by ~10%. Moreover, the position of linker chosen for dimerization also appears to
be important. Flavone dimer 7 (5─5 coupled) displayed lower efficacy than dimer 8 (3ˋ─3ˋ cou-
pled) despite the fact that 7 is an octasulfated NSGM, whereas 8 is a hexasulfated agent.
To enhance the possibility of more promising inhibitors, we coupled the flavone moiety
with the quinazolinone moiety, which resulted in three NSGMs 10–12 having different linker
Table 2. Inhibition Profiles of Human Factor XIIIa (FXIIIa), Human α-Thrombin (α-Th), Human Factor Xa (FXa), and Papain by Iodoacetamide (IAA)
and the NSGMs 13 and 14.a
Inhibitor IC50 (μM) HS ΔY (%)
IAA (FXIIIa) 2.9 ± 0.4b 0.8 ± 0.2 105 ± 10
13 (FXIIIa) 36.2 ± 4.5 0.9 ± 0.2 98 ± 11
14 (FXIIIa) 118.0 ± 49.9 1.1 ± 0.5 93 ± 30
13 (α-Th) >930 NDc ND
13 (FXa) 313.5 ± 119.6 0.9 ± 0.4 71 ± 22
13 (Papain) >1000 ND ND
a The IC50, HS, and ΔY values were obtained following non-linear regression analysis of direct inhibition of FXIIIa, α-Th, FXa, or papain in appropriate
TrisHCl buffers of pH 7.4–8.0 at 37°C containing appropriate concentrations of NaCl and CaCl2. See Materials and Methods for details.
b Errors represent ± 1 S.E.
c Not determined.
doi:10.1371/journal.pone.0160189.t002
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lengths. Although the three molecules were only pentasulfated, they exhibited80% FXIIIa
inhibition at 200 μM concentration. NSGM 10 was the most potent; however, it failed to induce
more than 27% inhibition at 20 μM concentration. It is important to mention here that several
disulfated homodimeric quinazolinone–based NSGMs (structures are not shown) were also
screened against FXIIIa without much success. This implied that the flavone moiety was the
favored scaffold for FXIIIa inhibition. This led to the study of flavone homotrimer 13, which is
the best inhibitor identified in this study. Even here, the linker length (propylenic versus ethyl-
enic) was found to be crucial. Homotrimer 14 displayed reduced inhibition potency in compar-
ison to homotrimer 13.
Previous studies have shown that polyanion-binding proteins do not necessarily rely on
high sulfation level of their ligands but also on the 3-dimentional orientation of the sulfate
groups. For example, factor XIa was found to preferentially recognize globular NSGMs [45],
while antithrombin interacted better with linear sulfated molecules [46]. To test the impact of
sulfate group orientation on FXIIIa inhibition, we studied NSGM 15. This molecule contains
similar number of sulfate groups as compared to 13 but has a more globular shape. Inhibitor
15 was about 2-fold less active than the trimer 13 at 200 μM concentration.
Finally, the backbone of FXIIIa inhibitors appears to be very critical. Whereas most NSGMs
exhibit some inhibition potential, the GAGs (16–22), which are perhaps more highly sulfated,
display very poor inhibition characteristics (concentrations<250 μM). UFH 16 has no direct
FXIIIa inhibition property despite the fact that it was found to bind to FXIIIa fairly well (KD of
2.4 μM, Fig 3C). Inhibitor 13 was found to bind to FXIIIa with a KD value of ~25 μM (Fig 3B).
Overall, these results highlight the significance of the aromatic scaffold of NSGMs for inhibit-
ing human FXIIIa.
Mechanism of FXIIIa Inhibition by NSGM 13
To understand the basis for 13’s FXIIIa inhibitory potential, the kinetics of dansylcadaverine
conjugation with dimethylcasein by FXIIIa was studied with and without the inhibitor using
the bisubstrate fluorescence assay [47]. At a fixed concentration of dimethylcasein (5 mg/mL),
the initial rate of conjugation increased in a hyperbolic manner with increasing concentration
of dansylcadaverine (Fig 4A) in the presence as well as absence of inhibitor 13. Analysis using
the Michaelis equation led to KM values for dansylcadaverine of 123.2 μM and 27.3 μM in the
Fig 3. Interaction of human FXIIIa and α-thrombin (α-Th) with NSGM 13 and UFH. (A) The inhibition of FXIIIa (●) and α-Th () by NSGM 13
was measured spectrofluorometrically through a bisubstrate, fluorescence-based transglutamination assay (FXIIIa) or chromogenic substrate
assay (α-Th) at pH 7.4/8.0 and 37°C. Solid lines represent sigmoidal fits to the data to obtain IC50, HS, YM, and YO using Eq 1. (B)
Spectrofluorometric measurement of the affinity of human FXIIIa for inhibitor 13 at pH 8.0 and 37°C using the intrinsic tryptophan fluorescence
(λEM = 348 nm, λEX = 280 nm). Solid lines represent nonlinear regressional fits using quadratic Eq 2. (C) Spectrofluorimetric measurement of the
affinity of human FXIIIa for UFH at pH 8.0 and 37°C using the intrinsic tryptophan fluorescence (λEM = 348 nm, λEX = 280 nm). Solid lines represent
nonlinear regressional fits using the standard Hill Eq 3. See details in Materials and Methods.
doi:10.1371/journal.pone.0160189.g003
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absence and presence of 13, respectively (Table 3). This represents an increase of ~4.5-fold in
dansylcadaverine binding affinity in the presence of 13 at 120 μM. Likewise, the VMAX also
decreased ~3-fold in the presence of the inhibitor.
To derive kinetic constants for dimethylcasein, we used a fixed, high concentration of dan-
sylcadaverine (250 μM) and studied the initial rate of conjugation, as described above. As
expected, a hyperbolic profile was observed with increasing concentration of dimethylcasein
(0–5 mg/mL) (Fig 4B) from which the KM and VMAX were calculated. The KM for dimethylca-
sein in the absence of 13 was measured to be 1.6 mg/mL, which essentially remained invariant
in the presence of the inhibitor at 40 μM (Table 3). In contrast, VMAX decreased ~2.5-fold in
the presence of 13 at 40 μM.
It is important to note that FXIIIa-mediated reaction is a bisubstrate conjugation reaction
and its interaction with 13 is sensed differently by the two substrates. Whereas the KM of dan-
sylcadaverine decreased upon 13 binding, it did not change for N,N-dimethylcasein. Yet, for
both substrates, there was a decrease in the VMAX with the inhibitor concentration. This alludes
Fig 4. Michaelis−Menten kinetics of dansylcadaverine andN,N-dimethylcasein conjugation by human FXIIIa in the presence of NSGM 13.
The initial rate of conjugation at (A) various dansylcadaverine concentrations (0–750 μM) and fixed dimethylcasein concentration (5 mg/mL) or (B)
various dimethylcasein concentrations (0–5 mg/mL) and fixed dansylcadaverine concentration (250 μM) was measured spectrofluorometrically in
pH 8.0 buffer at 37°C. Solid lines represent nonlinear regressional fits to the data by the standard Michaelis−Menten Eq 4 to yield KM and VMAX.
See details in Materials and Methods.
doi:10.1371/journal.pone.0160189.g004
Table 3. Conjugation of Dansylcadaverine (DC) andN,N-Dimethylcasein (N,N-DMC) by Human FXIIIa in the Presence of NSGM 13.a
[13] (μM) [N,N-DMC] (mg/mL) [DC] (μM) KM VMAX (RFU/min) (x103) kcat (1/s) (x103) kcat/KM (1/M s) (x107)
0 5 0–750 123.2 ± 25.6b μM 98.4 ± 7.0 54.7 ± 3.8 44.4 ± 9.7
8 5 0–750 105.0 ± 23.2 μM 81.1 ± 5.9 45.1 ±3.3 43.0 ± 10.0
40 5 0–750 77.5 ± 18.6 μM 55.9 ± 4.1 31.1 ± 2.3 40.2 ± 10.1
120 5 0–750 27.3 ± 6.9 μM 32.2 ± 2.0 17.7 ± 0.9 33.4 ± 6.2
0 0–5 250 1.6 ± 0.2 mg/mL 93.5 ± 3.8 51.9 ± 2.1 71.1 ± 9.3
8 0–5 250 1.5 ± 0.3 mg/mL 61.0 ± 4.5 33.9 ± 2.5 49.9 ± 10.9
40 0–5 250 1.7 ± 0.4 mg/mL 37.7 ± 3.1 20.9 ± 1.7 27.1 ± 6.7
a KM and VMAX values of the two substrates (N,N-DMC: N,N-Dimethylcasein; DC: Dansylcadaverine) conjugation by human FXIIIa (0.03 μM) were measured
using ﬂuorescence spectroscopy (λEx = 360 nm and λEm = 550 nm) in 50 mM TrisHCl (pH 8.0) containing 10 mM CaCl2 and 100 mM NaCl at 37°C. RFU
indicates relative ﬂuorescence units. Average MWt of casein used is 22 kD.
b Error represents ±1 SE.
doi:10.1371/journal.pone.0160189.t003
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to an allosteric process. In these experiments inhibitor 13 was used at varying levels, of which
the highest concentration ensured that FXIIIa was essentially fully saturated and inhibited.
Thus overall, these results indicate that 13 acts as an uncompetitive inhibitor with respect to
the smaller substrate, i.e. dansylcadaverine, and as a noncompetitive inhibitor with respect to
the larger substrate, i.e. dimethylcasein.
While for uncompetitive inhibition, the inhibitor binds to FXIIIa-substrate complex only,
an ideal noncompetitive inhibition requires equal preference of the inhibitor for both enzyme
and enzyme–substrate complex. Because dansylcadaverine is the first substrate to engage
FXIIIa, the uncompetitive mechanism suggests simultaneous engagement of both the substrate
and the inhibitor by the enzyme. The reduction in rate of this reaction is likely to be conforma-
tional change in the active site, which most probably carries forward to the subsequent step
without much change in the affinity of dimethylcasein resulting in a non-competitive kinetics.
Although plausible, this explanation should be considered hypothetical and detailed kinetic
evaluation would be necessary to elucidate the parameters of this ping-pong process. Yet, both
mechanisms have to arise from allosteric binding of inhibitor 13 to FXIIIa, which induces dys-
function in its catalytic apparatus. Thus, NSGM 13 is the first allosteric modulator of FXIIIa
and likely to open up a major route in the design of FXIIIa inhibitors to treat associated
pathologies.
Selectivity of Inhibition by 13
One of the reasons behind targeting an allosteric site on human FXIIIa was to achieve selectiv-
ity of inhibition over closely related enzymes. To demonstrate this feature, hydrolysis of appro-
priate small tripeptidic chromogenic substrates of thrombin and factor Xa, two GAG-binding
proteins that play major roles in coagulation, was measured at pH 7.4 and 37°C (Fig 5A). The
IC50 values of inhibitor 13 against thrombin and factor Xa were>930 μM and 313.5 μM,
respectively (Table 2) suggesting a selectivity index of at least 26-fold and 9-fold, respectively.
Additionally, inhibition of factor Xa by 13 displayed an efficacy of 71% as opposed to nearly
Fig 5. Relative inhibition potency and reversibility of NSGM 13 toward human FXIIIa and related enzymes. (A) Residual activity (%) of
four enzymes in the presence of inhibitor 13. The inhibition of FXIIIa (●), factor Xa (□), thrombin (♦), and papain (Δ) by inhibitor 13was
studied by the corresponding assays at pH 7.4 and 37 °C as described in the Materials and Methods. Solid lines represent the sigmoidal
dose−response fits (Eq 1) to the data to obtain the values of IC50, ΔY, and HS. (B) Reversibility assay was performed at inhibitor 13
concentration of 100 μM (●) by adding increasing concentration of polybrene (0–3 mg/mL). Shown also the residual FXIIIa activity in the
presence of only polybrene () or only inhibitor 13 (100 μM) (□). Solid lines represent the sigmoidal fits to the data to obtain IC50 (or EC50), HS,
YM, and YO using Eqs 1 or 5, as described in the Materials and Methods.
doi:10.1371/journal.pone.0160189.g005
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100% displayed against FXIIIa. This is important as it further alludes to the allosteric nature of
NSGMs [48]. This also suggests that inhibitor 13 could be possibly modified so as to engineer
enhanced selectivity and partial inhibition (<100%) [48]. Finally, we studied 13 inhibition of
papain, a related cysteine protease. NSGM 13 demonstrated a selectivity index of at least
27-fold over papain (Table 2). Thus overall, the allosteric inhibitor 13 displays a good
selectivity.
Reversibility of Inhibition by 13
Because NSGMs were developed as alternatives to GAGs [49], we hypothesized that inhibition
of FXIIIa by NSGM 13 is most probably driven by electrostatic interactions between sulfate
groups and their counterparts Arg and Lys on FXIIIa. Therefore, we evaluated polybrene as a
rapid antidote of the binding of NSGM 13 to FXIIIa. Polybrene is a quaternary amine-based
cationic polymer, which is traditionally used to probe electrostatic interactions of GAGs with
their binding proteins [50]. Human FXIIIa was first treated with a high concentration of inhib-
itor 13 (100 μM) and the recovery of FXIIIa activity by polybrene studied spectro-fluorometri-
cally, as described above at pH 8.0 and 37°C (Fig 5B). The effective concentration of polybrene
to restore up to 85% of the original enzyme activity (EC50) were calculated and found to be
0.80 ± 0.05 mg/mL. It is important to emphasize here that polybrene did not affect FXIIIa
activity as measured by the bisubstrate fluorescence assay. Thus, this class of allosteric inhibi-
tors, in particular NSGM 13, appear to interact with FXIIIa through ionic interactions and its
inhibition is rapidly reversed by polybrene.
Effect of Inhibitor 13 on FXIIIa-Mediated Fibrin Polymerization
To assess the impact of inhibitor 13 on the primary physiologic function of FXIIIa, we used a
modified assay in which we monitored cross-linked fibrin formation following activation of
fibrinogen by thrombin in the presence of human FXIIIa. The reaction was carried out in 50
mM TrisHCl buffer of pH 7.4 containing 10 mM CaCl2. The formation of the crosslinked
fibrin was monitored spectrophotometrically at 405 nm and 25 °C. As depicted in Fig 6A, in
the presence of 5, 50, and 500 μM 13 fibrin formation decreased dose-dependently to about
87 ± 5%, 64 ± 4%, and 3.5 ± 3.5%, respectively. This suggests that NSGM 13 inhibits fibrin
polymerization in vitro. Likewise, a gel electrophoresis experiment revealed that NSGM 13
inhibited the formation of γ-γ polymers (~117 kD) at concentrations of 1000, 200, and 40 μM.
In fact, it appears that inhibitor 13 dose-dependently inhibits the FXIIIa-mediated polymeriza-
tion process, and therefore, the intensity (quantity) of α-, β-, γ-bands increased at least 2-fold
as the concentration of inhibitor 13 increases from 40 μM to 1000 μM (see S1 Fig). Overall,
inhibitor 13 was found to not only inhibit FXIIIa using dansylcadaverine and casein as sub-
strates, but also it did inhibit the physiologic function of FXIIIa i.e. fibrin polymerization.
To confirm that this phenomenon was mainly because of action of inhibitor 13 on FXIIIa,
the same experiment was repeated without adding either thrombin or FXIIIa. This resulted in
formation of only about 24 ± 4% and 13.5 ± 1.5% turbidity, respectively, as compared to the
control experiment. This implies that fibrin polymerization was inhibited due to the action of
13 on either thrombin or FXIIIa. We also evaluated the direct inhibition of human α-thrombin
by 13 using the corresponding standard chromogenic substrate hydrolysis assay. NSGM 13
was found to not inhibit human α-thrombin at the highest concentration tested of 930 μM (Fig
3A), which implies at least 26-fold selectivity for FXIIIa. Thus, inhibitor 13 appears to inhibit
the physiologic function of FXIIIa as measured by cross-linking of fibrin monomers. The IC50
of fibrin crosslinking inhibition was measured to be 76.3 μMwith an efficacy value of ~100%
under near physiologic conditions of pH 7.4 and 25°C (Fig 6B).
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Conclusions and Significance
For this study, we proposed that allosteric modulation of FXIIIa should be possible by targeting
one or more of the anion-binding site(s) on the A subunit of FXIIIa. We found that heparin
does bind to FXIIIa with a KD value of 2.4 μM, yet it does not inhibit its function. On the
Fig 6. Effect of NSGM 13 on FXIIIa-mediated fibrin crosslinking. (A) The formation of crosslinked fibrin
upon addition of aqueous solution of thrombin (2.5 μg/mL) to aqueous solution of fibrinogen (10 mg/mL) and
human FXIIIa (2.0 μg/mL) was measured spectrophotometrically at 405 nm and 25°C. The reaction was
carried out in 50 mM TrisHCl buffer of pH 7.4 containing 10 mMCaCl2 and in the presence or absence of
thrombin, FXIIIa, or NSGM 13 (5, 50, and 500 μM). (B) Relative fibrin crosslinking (%) of a solution containing
fibrinogen (10 mg/mL), FXIIIa (2.0 μg/mL), thrombin (2.5 μg/mL), and 10 mMCaCl2 in the presence of various
concentrations of NSGM 13was determined by measuring the absorbance of each well at 405 nm, pH 7.4,
and 25°C. Solid lines represent sigmoidal fits to the data to obtain IC50, HS, YM, and YO using Eq 1. See
details in Materials and Methods.
doi:10.1371/journal.pone.0160189.g006
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contrary, NSGM 13 was found to moderately bind and inhibit human FXIIIa with a KD of
25 μM and an IC50 of 36 μM. Allosteric inhibition of FXIIIa by 13 was suggested by Michaelis–
Menten kinetics and this induced inhibition of FXIIIa–mediated fibrin polymerization with
IC50 of 76 μM. Interestingly, similar molecule with the same flavonoid scaffold and number of
sulfate groups i.e., inhibitor 14 only inhibited FXIIIa weakly with and an IC50 of 118 μM. Struc-
turally, inhibitor 13 possesses two ethylene units bridging the three flavonoid moieties whereas
inhibitor 14 possesses two propylene linkers. The increased flexibility of the latter inhibitor
perhaps makes it less probable for the molecule to adopt an optimal three dimensional orienta-
tions of the sulfate and aromatic moieties which are better recognized by the anion-binding site
(s) of human FXIIIa. This indicates that small structural differences have significant impact on
the potency of flavonoid-based allosteric inhibitors of FXIIIa and suggests that further medici-
nal chemistry efforts should focus on optimizing the number and the position of sulfate groups
to engineer higher potency in addition to higher selectivity.
This work shows for the first time that allosteric modulation of FXIIIa is achievable by
exploiting the coupling between the heparin-binding site and enzyme’s active site. The interest-
ing aspect of this modulation is that NSGMs are able to induce inhibition but not GAGs. In
fact, it is this made even more interesting when one takes into account that heparin binding to
FXIIIa appears to be a cooperative process, as evidenced by the sigmoidal binding profile
(n = 1.9 ± 0.6; see Fig 3C). This implies that cooperativity does not automatically induce inhibi-
tion, i.e., not enough change in the structure of the active site. On the other hand, NSGM 13
interaction with FXIIIa appears to be a non-sigmoidal binding process, although inducing allo-
steric inhibition. The fundamental reason(s) for these differences remain to be understood.
The presence of aromatic/hydrophobic character in a FXIIIa ligand is likely to be critical.
This aspect has also been observed earlier for inhibition of thrombin [37, 38, 48] and factor XIa
[50]. As stated in an editorial some time ago [49], the combination of hydrophilic/negative
charge and aromatic/hydrophobic character in NSGMs introduces significant functional differ-
ences from the molecules that attempt to mimic–GAGs. These differences appear to arise from
the interaction of NSGMs with non-basic residues in addition to lysines and arginines, which
help originate an alternate network of coupled residues resulting in an alternate allosteric con-
formational change. Recent results suggest that multiple such networks exist in thrombin [51,
52], a highly plastic coagulation factor. This work shows that FXIIIa, despite being a completely
different type of enzyme from typical serine proteases of the coagulation cascade, exhibits simi-
lar allosterism.
In principle, allosteric inhibition of coagulation factors can induce homeostasis, a state
wherein pro-coagulation and anti-coagulation propensities are perfectly balanced [53]. Such a
state has not been possible to achieve with any of the orthosteric inhibitors, which is the pri-
mary reason for adverse consequences associated with all current drugs [5]. Achieving homeo-
stasis is challenging and NSGM 13 certainly does not display this property, as evidenced by the
nearly 100% inhibition of FXIIIa at saturation. However, the first group of NSGMs that point
to the possibility of inducing homeostasis have been devised for thrombin [37, 38, 48], which
suggest that it may be possible to design/discover such agents for FXIIIa.
Allosteric inhibitors offer several advantages over orthosteric inhibitors [24–27]. Allosteric
inhibitors tend to be more specific in recognition and function as allosteric sites of enzymes
belonging to the same superfamily tend to be less conserved as compared to their more similar
active sites. In principle therefore, allosteric inhibitors afford a better opportunity to develop
safer therapeutics. NSGM 13 does not exhibit this level of specificity, as evidenced by the simi-
larity of its inhibition of transglutaminase. Yet, it is able to select FXIIIa over thrombin, factor
Xa, and the cysteine protease papain. We predict that computational molecular modeling
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aided by co-crystal structures of the FXIIIa–13 and transglutaminase–13 complexes would
help design advanced agents that more selectively target FXIIIa.
Despite the interesting mechanistic aspect of NSGM 13, it is important to emphasize that
this study has been conducted in an isolated/purified system to establish the promising phe-
nomenon of allosteric modulation of FXIIIa’s enzymatic activity by targeting a putative anion-
binding site. Effect of this molecule on the whole coagulation process as determined in human
plasma or whole blood remains to be thoroughly investigated.
Overall, our work has presented initial evidence that an alternative approach to modulate
FXIIIa through allosterism is clearly possible, very promising and likely to engineer molecules
with reduced bleeding risks. Furthermore, the use of specific NSGMs to study mechanism of
action may enhance our understanding of the role of FXIIIa in hemostasis. Finally, this work
also suggests the possibility of NSGM-mediated allosteric modulation of other transglutami-
nases, which may have implications in other physiologic and/or pathologic processes.
Materials and Methods
Chemicals, Reagents, Analytical Chemistry, Enzymes, and Substrates
All anhydrous organic solvents were purchased from Sigma-Aldrich (St Louis, MO) or Fisher
(Waltham, MA) and used as such. Other solvents used were of reagent gradient and used as
purchased. Analytical TLC was performed using UNIPLATETM silica gel GHLF 250 um pre-
coated plates (ANALTECH, Newark, DE). Silica gel (200–400 mesh, 60 Å), fibrinogen, dansyl-
cadaverine, dithiothreitol (DTT), and N,N-dimethylcasein were from Sigma-Aldrich. Chemical
reactions sensitive to air or moisture were carried out under nitrogen atmosphere in oven-
dried glassware. Reagent solutions, unless otherwise noted, were handled under a nitrogen
atmosphere using syringe techniques. Flash chromatography was performed using Teledyne
ISCO (Lincoln, NE) Combiflash RF system and disposable normal silica cartridges of 30–50 μ
particle size, 230–400 mesh size and 60 Å pore size. The flow rate of the mobile phase was in
the range of 18 to 35 ml/min and mobile phase gradients of ethyl acetate/hexanes and CH2Cl2/
CH3OH were used to elute compounds. Human FXIIIa, α-thrombin, and factor Xa were
obtained from Haematologic Technologies (Essex Junction, VT). Stock solution of FXIIIa was
prepared in 50 mM TrisHCl buffer, pH 8.0, containing 10 mM CaCl2 and 100 mMNaCl. Stock
concentration of fibrinogen was prepared in 50 mM TrisHCl buffer, pH 7.4, containing 10 mM
CaCl2. Stock solution of thrombin and factor Xa were prepared in 20 mM TrisHCl buffer, pH
7.4, containing 100 mMNaCl, 2.5 mM CaCl2, 0.1% PEG8000, and 0.02% Tween80. Chromo-
genic substrates of thrombin (Spectrozyme TH) and of factor Xa (Spectrozyme FXa) were
obtained from Sekisui Diagnostics (Lexington, MA). Reagents for gel electrophoresis experi-
ment were from ThermoFisher Scientific (Waltham, MA). Papain, its chromogenic substrate
(N-α-benzoyl-L-arginyl-4-nitroanilide), and polybrene were all from Sigma-Aldrich. Papain
was prepared in 50 mM TrisHCl buffer, pH 7.4, containing 100 mMNaCl, 100 mMDTT, 2.5
mM CaCl2, 0.1% PEG8000, and 0.02% Tween80.
GAGs and NSGMs
All GAGs were obtained from commercial sources, while sulfated NSGMs were synthesized, as
reported earlier [54, 55]. Of these, 13 was synthesized as depicted in S1 File. Briefly, the natural
product quercetin 13a was treated with 3–4 equivalents of MOM-Cl in the presence of strong
base DIPEA at room temperature resulting in intermediates 13b and 13c with yields of 45%
and 55%, respectively. The intermediate 13b was regioselectively protected at positions-3, -7,
and -4’. The presence of extra equivalent of MOM-Cl resulted in intermediate 13c, which was
protected at all phenolic groups except for position-5. Intermediate 13d was then quantitatively
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prepared by base-mediated SN2 alkylation of 13c using the same amount of dibromoethane.
After that, 2.5 equivalents of K2CO3 was added to 13b in DMF followed by the addition of 2
equivalents of intermediate 13d, which led to the formation of per-protected trimeric flavone.
The MOM groups were then deprotected by refluxing the per-protected intermediate in
MeOH in the presence of catalytic amount of para-toluenesulfonic acid (p-TSA). Sulfation of
the resulting phenolic precursor was achieved using microwave-assisted protocol in which a
stirred solution of trimeric polyphenol in anhydrous CH3CN was treated with the base Et3N
(10 equiv. per −OH group) and the sulfating agent SO3/Me3N complex (6 equiv. per −OH) at
room temperature. The reaction mixture was microwaved for 8 h at 90°C resulting in the per-
sulfated trimer 13. The overall yield of the last three steps of coupling, deprotection, and sulfa-
tion was about 60% (see S1 File).
Chemical Characterization of Molecules
1H and 13C NMR were recorded on Bruker-400 MHz spectrometer in either CD3OD, CDCl3,
acetone-d6, D2O, or DMSO-d6. Signals, in part per million (ppm), are either relative to the
internal standard or to the residual peak of the solvent. The NMR data are reported as chemical
shift (ppm), multiplicity of signal (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet
of doublet, m = multiplet), coupling constants (Hz), and integration. ESI-MS of compounds
were recorded using Waters Acquity TQDMS spectrometer in positive or negative ion mode.
Samples were dissolved in methanol and infused at a rate of 20 μL/min. For HRMS measure-
ments, a Perkin Elmer AxION 2 TOFMS was used in negative ion mode. Ionization conditions
on both instruments were optimized for each compound to maximize the ionization of the par-
ent ion. Final sulfated products (1–15) were obtained in high overall yields (>50%), had>95%
purity, and their NMR and MS data were found to be identical to values reported earlier in lit-
erature [54, 55]. See S1 File.
Direct Inhibition of Human FXIIIa, Thrombin, Factor Xa, and Papain by
Sulfated Molecules
Direct inhibition of human FXIIIa was measured spectrofluorometrically by a bisubstrate, fluo-
rescence-based transglutamination assay at pH 8.0 and 37°C on a microplate reader (FlexSta-
tion III, Molecular Devices) (modified from earlier reports) [47, 56]. Briefly, to each well of a
96-well microplate containing 80 μL of 50 mM TrisHCl buffer, pH 8.0, containing 100 mM
NaCl, 10 mM CaCl2, and 2 mg/mL dimethylcasein was added 5 μL potential NSGM-based
inhibitor (0–20 mM aqueous solution) or vehicle, 5 μL DTT (20 mM), and 5 μL enzyme (0.12–
1.2 μM) at 37°C. After 5 min incubation, 5 μL of dansylcadaverine (2.5 mM) was rapidly added
and the residual enzyme activity was measured from the initial rate of increase in RFU (λEM =
550 nm, λEX = 360 nm). Relative residual enzyme activity (Y) as a function of the concentration
of sulfated molecule was fitted using logistic Eq 1 to obtain the potency (IC50), efficacy (ΔY)
and Hill slope (HS) of inhibition. In this equation, YM and Yo are the maximal and minimal
values of Y.
Y ¼ Y0 þ
YM  Y0
1þ 10ðlog½Inhibitor0logIC50ÞðHSÞ ð1Þ
Direct inhibition of thrombin, a GAG–binding protein, was measured using a chromogenic
substrate hydrolysis assay on a microplate reader (FlexStation III, Molecular Devices), as
reported earlier [37, 38]. Brieﬂy, to each well of a 96-well microplate containing 185 μL of 20
mM TrisHCl buffer, pH 7.4, containing 100 mMNaCl, 2.5 mM CaCl2, 0.1% PEG8000, and
0.02% Tween80 was added 5 μL of inhibitor 13 (0–20 mM) or vehicle, and 5 μL of thrombin
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(240 nM) at 25°C. After 10 min incubation, 5 μL of Spectrozyme TH (2 mM) was rapidly
added and the residual enzyme activity was measured from the initial rate of increase in A405.
Relative residual enzyme activity as a function of the inhibitor concentration was measured
and inhibition parameters were calculated using logistic Eq 1. Likewise, inhibition of factor Xa,
another GAG–binding protein, by inhibitor 13 was performed in a similar fashion using the
corresponding chromogenic substrate assay in pH 7.4 TrisHCl buffer at 37°C. The effective
concentrations of factor Xa and its substrate (Spectrozyme FXa) were 43.5 nM and 5 mM,
respectively.
Direct inhibition of papain, a cysteine protease, by inhibitor 13 was also evaluated using a
chromogenic substrate assay on a microplate reader (FlexStation III, Molecular Devices) as
reported earlier [15]. Briefly, to each well of a 96-well microplate containing 91 μL of 50 mM
TrisHCl buffer, pH 7.4, containing 100 mMNaCl, 100 mM DTT, 2.5 mM CaCl2, 0.1%
PEG8000, and 0.02% Tween80 was added 5 μL of inhibitor 13 (0–20 mM) or vehicle, and 3 μL
of papain (130 U/mL) at 37°C. After 5 min incubation, 1 μL of N-α-benzoyl-L-arginine
4-nitroanilide hydrochloride, the chromogenic substrate (17.7 mM) was rapidly added and the
residual enzyme activity was measured from the initial rate of increase in absorbance at 405
nm. Relative residual enzyme activity as a function of the inhibitor concentration was mea-
sured and inhibition parameters were calculated using logistic Eq 1.
Fluorescence–Based Binding Affinity of Inhibitor 13 and UFH to Human
FXIIIa
Fluorescence experiments were performed using a QM4 spectrofluorometer (Photon Technol-
ogy International, Birmingham, NJ) in 50 mM TrisHCl buffer, pH 7.4, containing 100 mM
NaCl and 10 mM CaCl2 at 37°C. The affinity of FXIIIa for either inhibitor 13 or UFH was mea-
sured using the change in the intrinsic tryptophan fluorescence (λEM = 348 nm, λEX = 280 nm)
at varying concentrations of the ligand [L]. The titrations were performed by adding aliquots
of 250 μM aqueous solution of inhibitor 13 or UFH to 200 μL solution of FXIIIa (127 nM) and
monitoring the fluorescence intensity at the appropriate λEM. The excitation and emission slits
were set to 1.0 mm. The observed change in fluorescence (ΔF) relative to initial fluorescence
(Fo) was fitted using Eq 2 (inhibitor 13) or Eq 3 (UFH) to obtain the dissociation constant (KD)
and the maximal change in fluorescence (ΔFMAX) at saturation. In Eq 3, the Hill coefficient “n”
is a measure of the cooperativity of binding. Each measurement was performed three times.
DF
F0
¼ DFMAX
F0

ð½FXIIIa0 þ ½130 þ KDÞ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½FXIIIa0 þ ½130 þ KDÞ2  4½FXIIIa0½130
q
2½FXIIIa0
ð2Þ
DF
Fo
¼ DFMAX 
½UFHn
ðKDÞn þ ½UFHn
ð3Þ
Michaelis–Menten Kinetics of Dansylcadaverine and N,N-
Dimethylcasein Conjugation Rate by Human FXIIIa
The initial rate of dansylcadaverine and N,N-dimethylcasein conjugation by FXIIIa was
obtained from the linear increase in fluorescence at λEM = 550 nm (λEX = 360 nm). The initial
rate was measured as a function of various concentrations of 1) dansylcadaverine (0–15 mM;
effective concentrations in the well were 0−750 μM) at fixed saturating concentration of
dimethyl-casein (5 mg/mL) or 2) dimethylcasein (0–5 mg/mL) at fixed concentration of
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dansylcadaverine (5 mM; effective concentration was 250 μM) in the absence or presence of
inhibitor 13 (0, 8, 40, or 120 μM) in 50 mM TrisHCl buffer, pH 8.0, containing 100 mMNaCl,
1 mM DTT, and 10 mM CaCl2 at 37°C. The data was fitted using the standard Michaelis
−Menten Eq 4 to determine the KM and VMAX.
Vi ¼
VMAX  ½S
KM þ ½S
ð4Þ
Polybrene Reversibility of FXIIIa Inhibition by NSGM 13
To assess the in vitro reversibility of FXIIIa inhibition, the activity profiles were measured in
the presence of increasing concentrations of polybrene and inhibitor 13 (100 μM) at pH 7.4
and 37°C. Generally, each well of the 96-well microplate contained 80 μL of 50 mM TrisHCl
buffer of pH 8.0 containing 100 mMNaCl, 1 mMDTT, 10 mM CaCl2, and 2 mg/mL dimethyl-
casein to which 5 μL of inhibitor 13 (2 mM) or vehicle, 5 μL of FXIIIa (stock of 0.6 μM), and
5 μL of prolybrene (0–60 mg/mL; effective concentrations were 0–3 mg/mL) were sequentially
added. After a 5 min incubation, 5 μL of dansylcadaverine (2.5 mM; effective concentration in
the well was 125 μM) was rapidly added and the restored FXIIIa activity was measured from
the initial rate of increase in fluorescence at λEM = 550 nm (λEX = 360 nm). Stock of polybrene
was serially diluted to give 7 different aliquots in the wells. Relative restored FXIIIa activity at
each concentration of polybrene was calculated from the ratio of FXIIIa activity in the presence
and absence of the reversing agent. Eq 5 was used to fit the dose dependence of restored trans-
glutaminase activity to obtain the effective concentration of reversing agent required to restore
50% of enzyme activity at specific inhibitor concentration (EC50) and the efficacy (ΔY) of
reversing process.
Y ¼ Y0 þ
YM  Y0
1þ 10ðlog½polybrene0logEC50ÞðHSÞ ð5Þ
Effect of Inhibitor 13 on FXIIIa-Mediated Fibrin Polymerization
This effect was determined by measuring the absorbance of an aqueous mixture of fibrinogen,
human FXIIIa, and α-thrombin at 25°C on a microplate reader (FlexStation III, Molecular
Devices). This experiment is a modified platform of a standard turbidity test [15, 17]. In this
test, a 170 μL of the above mixture was formed by mixing 1) a 60 μL solution of fibrinogen (10
mg/mL) and human FXIIIa (2 μg/mL) in 50 mM TrisHCl buffer, pH 7.4, containing 10 mM
CaCl2, 2) a 30 μL solution of inhibitor 13 (5, 50, or 500 μM) or vehicle, and 3) an 80 μL solution
of thrombin (2.5 μg/mL) in 50 mM TrisHCl buffer, pH 7.4, containing 10 mM CaCl2. After 15
min incubation, the absorbance was measured at 405 nm. Same exercise was repeated without
adding human α-thrombin or FXIIIa. The experiment was also performed at 24 different con-
centrations of inhibitor 13 (0–1177 μM). At each concentration, the relative residual FXIIIa
activity causing fibrin polymerization (as indicated by turbidity) was determined by measuring
the well absorbance at 405 nm. Relative residual enzyme activity (Y) as a function of the con-
centration of inhibitor 13 was fitted using logistic Eq 1 to obtain the IC50, ΔY, and HS of
inhibition.
The effect of inhibitor 13 on fibrin polymerization was further investigated by gel electro-
phoresis as reported earlier [15] (See S1 Fig). A solution containing 13 mg/ml fibrinogen and
2.0 μg/mL FXIIIa (in the aforementioned TrisHCl buffer of pH 7.4 containing 10 mM CaCl2)
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was clotted in the presence and absence of human α-thrombin (2.5 μg/mL). The resulting mix-
ture was either incubated with inhibitor 13 (1000, 200, and 40 μM) or buffer. The clots were
incubated for 24 hrs at room temperature before the addition of denaturing buffer of 25 mM
NaH2PO4, 5.7 M urea, 1.9% (w/v) SDS and 1.9% (w/v) DTT and then incubated overnight at
25°C. Samples were boiled in a water bath for 10 min before centrifugation at 12 000 g at 20°C
for 3 min. The supernatants were examined by SDS/PAGE on homogeneous 7.5% cross-linked
gels and stained with Coomassie Brilliant Blue followed by silver stain.
Supporting Information
S1 Fig. Evaluation of FXIIIa-mediated fibrin polymerization by gel electrophoresis in the
presence of inhibitor 13. The gel electrophoresis experiment shows a dose-dependent effect of
inhibitor 13 (1000, 200, and 40 μM) on fibrin cross-linking.
(PDF)
S1 File. Synthesis and characterization of NSGM 13. Synthetic scheme and synthetic proto-
cols for inhibitor 13 and its precursors are provided. Characterization data (1H and 13C NMR,
and MS/ESI) of the flavonoid trimer 13 and its precursors are also provided.
(PDF)
S1 Table. Evaluation of enzyme concentration effect on NSGM 13 inhibition parameters.
Inhibition parameters (IC50,HS, and ΔY) of inhibitor 13 toward human FXIIIa using different
enzyme concentrations (0, 6, 18, and 30 nM).
(PDF)
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